向生物制药公司将在虚拟会议上展示其子语言药物技术,目标是在2025年底提交FDA的子语言阿司匹林. Aspire Biopharma to present its sublingual drug tech at a virtual conference, targeting FDA submission for a sublingual aspirin in late 2025.

Aspire Biopharma （ASBP） 将于 2025 年 10 月 8 日至 9 日在 Noble Capital Markets 2025 年新兴增长虚拟股票会议上发表演讲，重点介绍其正在申请专利的舌下给药技术。 Aspire Biopharma (ASBP) will present at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8–9, 2025, highlighting its patent-pending sublingual drug delivery technology. 该公司计划在2025年下半年向FDA提交其主导计划 - - 舌下高剂量阿司匹林的新药申请. The company aims to submit a New Drug Application for its lead program, sublingual high-dose aspirin, to the FDA in the second half of 2025. 其他里程碑包括在 2026 年初至中期之前完成配方并启动舌下含服勃起功能障碍药物和无针索马鲁肽制剂的 1 期研究。 Additional milestones include finalizing formulations and initiating Phase 1 studies for a sublingual erectile dysfunction medication and a needle-free semaglutide formulation by early to mid-2026. 该技术旨在通过直接通过口腔、绕过胃肠道向血液中提供药物,提高药物有效性,减少副作用。 The technology seeks to enhance drug effectiveness and reduce side effects by delivering medications directly into the bloodstream via the mouth, bypassing the gastrointestinal tract. 该平台设计用于使用小型和大型分子药物、营养学和补充剂。 The platform is designed for use with small and large molecule drugs, nutraceuticals, and supplements. 前瞻性说明面临风险和不确定性。 Forward-looking statements are subject to risks and uncertainties.